Los Angeles-based EntroGen, Inc. has launched a PCR-based Microsatellite Instability (MSI) Detection Kit designed for research use, targeting laboratories equipped with standard qPCR instrumentation. The assay offers a streamlined approach to detecting MSI, a molecular signature present in a subset of colorectal cancers.
Thermo Fisher Scientific has launched the Gibco Expi293 PRO Expression System, a next-generation HEK293-based platform engineered to address persistent challenges in producing difficult-to-express proteins for therapeutic development and structural biology research.
Cambridge-based Owlstone Medical has been awarded up to US$49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop a multi-cancer early detection test that can be performed at home using breath and urine samples. The funding forms part of ARPA-H’s Platform Optimising SynBio for Early Intervention and Detection in Oncology (POSEIDON) programme, […]
French pharmaceutical company Theranexus has announced its transformation into THX Pharma, marking a strategic pivot from biotechnology research towards regulatory approval and commercial deployment of treatments for rare neurological diseases. The rebranding of the Lyon-based company positions it to advance two lead drug candidates through registration and international market access.
Neogap Therapeutics AB has been granted Chinese patent protecting its proprietary method for expanding tumour-specific T cells, marking a significant milestone in the company’s international intellectual property strategy. The patent, which provides legal protection until 2038, covers a core manufacturing process for the company’s personalised cell-based immunotherapy, pTTL, currently under evaluation in Phase I/II clinical […]
French biotechnology company EVerZom has closed a €10 million funding round to support clinical development of its exosome-based therapeutic platform, with lead candidate EVerGel set to enter human trials in 2026 for treatment of complex perianal fistulas in Crohn’s disease.
Nabsys 2.0, LLC presented data on its OhmX™ Platform at the American Society of Human Genetics (ASHG) Annual Meeting in Boston, Massachusetts, from 14-18 October 2025. The presentations demonstrated applications of electronic genome mapping (EGM) technology in multiple disease states, including interstitial cystitis/bladder pain syndrome, hematological malignancies, and repeat expansion disorders.
SPT Labtech (Melbourn, UK) and 10x Genomics (Pleasanton, California) have established a strategic partnership aimed at automating single cell research workflows.
Celonic Group, a biologics contract development and manufacturing organisation based in Basel, Switzerland, has entered into a strategic alliance with CARBOGEN AMCIS to establish an end-to-end platform for antibody-drug conjugate (ADC) production. The collaboration combines Celonic’s upstream biologics capabilities with CARBOGEN AMCIS’s downstream expertise in payload synthesis, conjugation chemistry, and sterile fill-finish operations.
UK laboratory professionals are increasingly using artificial intelligence tools without adequate understanding of their functionality or associated risks, according to a new industry report examining AI implementation in scientific research environments.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
